Joyce Antal

2.6k total citations · 1 hit paper
33 papers, 1.8k citations indexed

About

Joyce Antal is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Joyce Antal has authored 33 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Surgery and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Joyce Antal's work include Cancer Immunotherapy and Biomarkers (15 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Lung Cancer Research Studies (6 papers). Joyce Antal is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Bladder and Urothelial Cancer Treatments (9 papers) and Lung Cancer Research Studies (6 papers). Joyce Antal collaborates with scholars based in United States, Canada and South Korea. Joyce Antal's co-authors include Xiaoping Jin, Ashok Gupta, Mary Jane Thomassen, Herbert Wiedemann, Peter H. O’Donnell, Jingsong Zhang, Jae‐Lyun Lee, Terence W. Friedlander, Christophe Massard and Noah M. Hahn and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Joyce Antal

32 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

2017 664 citations Joyce Antal, Xiaoping Jin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce Antal United States	19	1.1k	552	552	375	300	33	1.8k
Satoshi Kuboki Japan	27	636 0.6×	710 1.3×	296 0.5×	428 1.1×	662 2.2×	107	2.0k
Yoshito Hayashi Japan	23	231 0.2×	437 0.8×	476 0.9×	248 0.7×	505 1.7×	109	1.6k
Jérôme Alexandre France	20	823 0.7×	302 0.5×	528 1.0×	204 0.5×	360 1.2×	100	1.7k
Klaus Baumann Germany	22	1.0k 0.9×	319 0.6×	421 0.8×	189 0.5×	378 1.3×	84	2.2k
Jianping Zhang China	19	427 0.4×	129 0.2×	243 0.4×	364 1.0×	469 1.6×	67	1.6k
Sergey Orlov Russia	21	867 0.8×	276 0.5×	1.0k 1.9×	181 0.5×	804 2.7×	149	2.0k
Aiguo Lu China	29	988 0.9×	458 0.8×	537 1.0×	287 0.8×	877 2.9×	96	2.1k
Weijian Guo China	15	589 0.5×	262 0.5×	572 1.0×	71 0.2×	304 1.0×	72	1.4k
Tomoyuki Nagai Japan	24	528 0.5×	325 0.6×	409 0.7×	147 0.4×	599 2.0×	95	1.7k
Ilaria Ruffilli Italy	27	528 0.5×	188 0.3×	237 0.4×	405 1.1×	469 1.6×	54	2.2k

Countries citing papers authored by Joyce Antal

Since Specialization

Citations

This map shows the geographic impact of Joyce Antal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Antal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Antal more than expected).

Fields of papers citing papers by Joyce Antal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Antal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Antal. The network helps show where Joyce Antal may publish in the future.

Co-authorship network of co-authors of Joyce Antal

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce Antal. A scholar is included among the top collaborators of Joyce Antal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce Antal. Joyce Antal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Weiss, Jared, Jerome H. Goldschmidt, Zoran Andrić, et al.. (2021). Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies. Clinical Lung Cancer. 22(5). 449–460. 48 indexed citations

Hussein, Maen, Donald Richards, Ivan Sinielnikov, et al.. (2021). Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies. Cancer Management and Research. Volume 13. 6207–6218. 16 indexed citations

Beck, Thaddeus, David Richards, Richy Agajanian, et al.. (2021). MO01.40 Trilaciclib has Myelopreservation Benefits in Patients with Small Cell Lung Cancer Treated with Chemotherapy, Irrespective of Age. Journal of Thoracic Oncology. 16(1). S32–S33. 1 indexed citations

Zając, M, Jiabu Ye, Pralay Mukhopadhyay, et al.. (2020). Optimal PD-L1–high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. PLoS ONE. 15(4). e0231936–e0231936. 16 indexed citations

Hart, Lowell L., Renata Ferrarotto, Zoran Andrić, et al.. (2020). Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study. Advances in Therapy. 38(1). 350–365. 82 indexed citations

Tan, Antoinette R., Gail S. Wright, Anu Thummala, et al.. (2019). Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. The Lancet Oncology. 20(11). 1587–1601. 86 indexed citations

Aghajanian, Carol, Katherine M. Bell‐McGuinn, Howard A. Burris, et al.. (2018). A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Investigational New Drugs. 36(6). 1016–1025. 44 indexed citations

Zając, Magdalena, Anne-Marie Boothman, Yong Ben, et al.. (2018). Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma. Archives of Pathology & Laboratory Medicine. 143(6). 722–731. 18 indexed citations

Antonia, Scott, Julie R. Brahmer, Samir N. Khleif, et al.. (2016). Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi421–vi421. 32 indexed citations

10.

Segal, Neil H., S.‐H.I. Ou, Ani Sarkis Balmanoukian, et al.. (2016). Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Annals of Oncology. 27. vi328–vi328. 30 indexed citations

11.

Balmanoukian, Ani Sarkis, Scott Antonia, Ross Stewart, et al.. (2016). A Phase 1 study of MEDI1873 in adult patients with select advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS3099–TPS3099. 1 indexed citations

12.

Abou‐Alfa, Ghassan K., Bruno Sangro, Michael A. Morse, et al.. (2016). Phase 1/2 study of durvalumab and tremelimumab as monotherapy and in combination in patients with unresectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 34(15_suppl). TPS3103–TPS3103. 6 indexed citations

13.

Bauman, John W., Joyce Antal, Laurel M. Adams, et al.. (2010). Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Investigational New Drugs. 30(2). 662–671. 6 indexed citations

14.

Yates, Stephen L., et al.. (2000). Amyloid β and Amylin Fibrils Induce Increases in Proinflammatory Cytokine and Chemokine Production by THP‐1 Cells and Murine Microglia. Journal of Neurochemistry. 74(3). 1017–1025. 178 indexed citations

15.

Antal, Joyce, et al.. (1996). Surfactant Suppresses NF-κB Activation in Human Monocytic Cells. American Journal of Respiratory Cell and Molecular Biology. 14(4). 374–379. 60 indexed citations

16.

Thomassen, Mary Jane, et al.. (1995). Regulation of Human Alveolar Macrophage Inflammatory Cytokines by Tyloxapol: A Component of the Synthetic Surfactant Exosurf. Clinical Immunology and Immunopathology. 77(2). 201–205. 25 indexed citations

17.

Bukowski, Ronald M., G. Thomas Budd, Jacqueline A. Gibbons, et al.. (1994). Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects.. Journal of Clinical Oncology. 12(1). 97–106. 26 indexed citations

18.

Thomassen, Mary Jane, Joyce Antal, Mary J. Connors, et al.. (1993). Immunomodulatory Effects of Recombinant Interleukin-3 Treatment on Human Alveolar Macrophages and Monocytes. Journal of Immunotherapy. 14(1). 43–56. 5 indexed citations

19.

Thomassen, Mary Jane, David P. Meeker, Joyce Antal, Mary J. Connors, & Herbert Wiedemann. (1992). Synthetic Surfactant (Exosurf) Inhibits Endotoxin-stimulated Cytokine Secretion by Human Alveolar Macrophages. American Journal of Respiratory Cell and Molecular Biology. 7(3). 257–260. 87 indexed citations

20.

Thomassen, Mary Jane, M Ahmad, Barbara P. Barna, et al.. (1991). Induction of cytokine messenger RNA and secretion in alveolar macrophages and blood monocytes from patients with lung cancer receiving granulocyte-macrophage colony-stimulating factor therapy. Lung Cancer. 7(5). 331–331. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact